Biotechnology - Rare diseases, Biogen Idec, Hematology


Biogen Idec files for US approval of long-acting hemophilia A treatment


US biotech firm Biogen Idec (Nasdaq: BIIB) says it has submitted a Biologics License Application (BLA)…

Biogen IdecBiotechnologyNorth AmericaRare diseasesRegulationrFVIIIFc

Positive Ph III results for Biogen Idec and SOBI's hemophilia B agent


US biotech firm Biogen Idec (Nasdaq: BIIB) and partner Swedish Orphan Biovitrum (STO: SOBI) have announced…

Biogen IdecBiotechnologyEuropeNorth AmericaPharmaceuticalRare diseasesRegulationResearchrFIXFcSobiSwedish Orphan Biovitrum

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million


US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

Biogen Idec and Isis Pharma ink deal on targeting myotonic dystrophy


In a second accord between the US biotech companies this year, Biogen Idec (Nasdaq: BIBB) and Isis Pharmaceuticals…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingRare diseasesResearch

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra


The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

Isis Pharma could earn $299 million from Biogen Idec deal


US biotech firm Biogen Idec (Nasdaq: BIIB) has entered into an exclusive, worldwide option and collaboration…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingRare diseasesResearch

Back to top